Literature DB >> 16681009

[Etanercept (Enbrel) for the treatment of moderate to severe plaque type psoriasis].

C Piérard-Franchimont1, G E Piérard.   

Abstract

Etanercept (Enbrel) is a soluble tumour necrosis factor (TNF) receptor drug. By this mechanism, it inhibits the effects of TNF-alpha involved in the pathogenesis of psoriasis. Enbrel is approved for the treatment of moderate to severe chronic plaque psoriasis, and also for psoriatic arthritis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16681009

Source DB:  PubMed          Journal:  Rev Med Liege        ISSN： 0370-629X


  1 in total

1.  'Psoriasis 1' reduces psoriasis‑like skin inflammation by inhibiting the VDR‑mediated nuclear NF‑κB and STAT signaling pathways.

Authors:  Wen Sun; Yang Gao; Xianhua Yu; Yuan Yuan; Jun Yi; Zhen Zhang; Yuxing Cheng; Yong Li; Xing Peng; Xushan Cha
Journal:  Mol Med Rep       Date:  2018-07-09       Impact factor: 2.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.